Detection of c-fos expression in benign and malignant musculoskeletal lesions
Jason S. Weisstein
Department of Orthopaedic Surgery, University of California at San Francisco, San Francisco, CA, USA
Search for more papers by this authorRobert J. Majeska
Department of Orthopaedics, The Mount Sinai Medical Center, New York, NY, USA
Search for more papers by this authorMichael J. Klein
Department of Orthopaedics, The Mount Sinai Medical Center, New York, NY, USA
Search for more papers by this authorCorresponding Author
Thomas A. Einhorn
Department of Orthopaedic Surgery, 8th Floor, Boston University Medical Center, Doctors Office Building, 720 Harrison Avenue, Boston, MA 02118-2393, USA
Department of Orthopaedic Surgery, 8th Floor, Boston University Medical Center, Doctors Office Building, 720 Harrison Avenue, Boston, MA 02118-2393, USA, Tel.: +1-617-638-8435Search for more papers by this authorJason S. Weisstein
Department of Orthopaedic Surgery, University of California at San Francisco, San Francisco, CA, USA
Search for more papers by this authorRobert J. Majeska
Department of Orthopaedics, The Mount Sinai Medical Center, New York, NY, USA
Search for more papers by this authorMichael J. Klein
Department of Orthopaedics, The Mount Sinai Medical Center, New York, NY, USA
Search for more papers by this authorCorresponding Author
Thomas A. Einhorn
Department of Orthopaedic Surgery, 8th Floor, Boston University Medical Center, Doctors Office Building, 720 Harrison Avenue, Boston, MA 02118-2393, USA
Department of Orthopaedic Surgery, 8th Floor, Boston University Medical Center, Doctors Office Building, 720 Harrison Avenue, Boston, MA 02118-2393, USA, Tel.: +1-617-638-8435Search for more papers by this authorAbstract
The proto-oncogene c-fos has been implicated in the development of both benign and malignant lesions of bone. Although c-fos expression in such lesions has been well studied in transgenic mouse models, less is known about its role in human musculoskeletal pathology. To clarify this relationship, we used in situ hybridization to localize c-fos m-RNA transcripts in 26 fibrous lesions (eight cases of extra-abdominal fibromatosis and six cases each of fibrous dysplasia, fibrosarcoma, and malignant fibrous histiocytoma of bone) as well as six chondrosarcomas and eight conventional high grade osteosarcomas. We found detectable levels of c-fos expression in tissues from each type of lesion tested. Moreover, all fibrous lesions consistently demonstrated high levels of expression in a majority of cells in each lesion. Chondrosarcomas and osteosarcomas exhibited more heterogeneity in c-fos expression than fibrous tissues. Three of six chondrosarcomas showed moderate expression of c-fos while only one of six was considered high. Similarly, only three of eight osteosarcomas had high expression of c-fos. These findings indicate that the expression of c-fos may be important in the development of a broad range of fibrous lesions as well as in bone and cartilaginous tumors. Additionally, this is the first report, to our knowledge, of detectable c-fos m-RNA in human chondrosarcoma. © 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.
References
- 1 Angel P, Karin M. The role of jun, fos, and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129–57.
- 2 Barrios C, Castresana JS, Ruis J, Kreicbergs A. Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. J Orthop Res 1993; 11: 556–63.
- 3 Bogenmann E, Moghadam H, DeClerck YA, Mock A. C-Myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res 1987; 47: 3808–14.
- 4 Candeliere GA, Glorieux FH, Prud'homme J, St.-Arnaud R. Increased expression of the c-fos proto-oncogene in bone marrow from patients with fibrous dysplasia. N Engl J Med 1995; 332: 1546–51.
- 5 Castresana JS, Barrios C, Gomez L, Kreicbergs A. Amplification of the c-myc proto-oncogene in human chondrosarcoma. Diagn Mol Pathol 1992; 1: 235–8.
- 6 Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human α2(I) collagen (COL1A2) promoter activity by transforming growth factor-β. J Biol Chem 1996; 271: 3272–8.
- 7 Clohisy JC, Scott DK, Brakenhoff KD, Quinn CO, Partridge NC. Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol Endocrinol 1992; 6: 1834–42.
- 8 Crabb ID, Hughes SS, Hicks DG, Puzas JE, Tsao GJY, Rosier RN. Nonradioactive in situ hybridization using digoxigeninlabeled oligonucleotides. Am J Pathol 1992; 141: 579–89.
- 9 Finkel JP, Biskis BO, Jinkins PB. Virus induction of osteosarcomas in mice. Science 1966; 151: 698–701.
- 10
Finkel JP,
Reilly Jr CA,
Biskis BO.
Viral etiology of bone cancer.
Front Radiat Ther Oncol
1975;
10: 28–39.
10.1159/000398246 Google Scholar
- 11 Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumors of the skeleton. Virchows Arch 1998; 432: 515–9.
- 12 Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, et al. c-Myc and c-fos in human osteosarcoma: prognostic value of m-RNA and protein expression. Oncology 1998; 55: 556–63.
- 13 Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 1984; 311: 433–8.
- 14 Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 1993; 122: 685–701.
- 15 Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443–8.
- 16 Haase M, Koslowski R, Lengnick A, Hahn R, Wenzel KW, Schuh D, et al. Cellular distribution of c-jun and c-fos in rat lung before and after bleomycin induced injury. Virchows Arch 1997; 431: 441–8.
- 17 Honoki K, Tsutsumi M, Toshifumi T, Kondoh S, Shiraiwa K, Miyauchi Y, et al. Expression of the transin, c-fos, and c-jun genes in rat transplantable osteosarcomas and malignant fibrous histiocytomas. Mol Carcinog 1992; 6: 122–8.
- 18 Hoyland J, Sharpe PT. Upregulation of c-fos protoncogene expression in pagetic osteoclasts. J Bone Miner Res 1994; 9: 1191–4.
- 19 Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, et al. Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 1989; 80: 6–9.
- 20 Krontiris TG. Oncogenes. N Eng J Med 1995; 333: 303–6.
- 21 Labelle Y, Bussieres J, Courjal F, Goldring MB. The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. Oncogene 1999; 18: 3303–8.
- 22 Lee K, Deeds JD, Chiba S, Masako U, Bond AT, Segre GV. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 1994; 134: 441–50.
- 23 Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c-met) in benign and malignant bone tumors. Mod Pathol 1997; 10: 832–8.
- 24 Ohta S, Yamamuro T, Lee K, Okumura H, Kasai R, Hiraki Y, et al. Fracture healing induces expression of the proto-oncogene c-fos in vivo. FEBS Lett 1991; 284: 42–5.
- 25 Pearman AT, Chou WY, Bergman KD, Pulumati MR, Partridge NC. Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. J Biol Chem 1996; 271: 25715–21.
- 26
Pompetti F,
Rizzo P,
Simon RM,
Fredlin B,
Mew DJ,
Pass HI, et al.
Oncogene alterations in primary recurrent and metastatic bone tumors.
J Cell Biochem
1996;
63: 37–50.
10.1002/(SICI)1097-4644(199610)63:1<37::AID-JCB3>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 27 Ruther U, Garber C, Komitowski D, Muller R, Wagner EF. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 1987; 325: 412–6.
- 28 Ruther U, Komitowski D, Schubert FR, Wagner EF. c-Fos expression induces bone tumors in transgenic mice. Oncogene 1989; 4: 861–5.
- 29 Sandberg M, Vuorio T, Hirvonen H, Alitalo K, Vuorio E. Enhanced expression of TGF-beta and c-fos mRNAs in the growth plates of developing human long bones. Development 1988; 102: 461–70.
- 30 Schon A, Michiels L, Janowski M, Merregaert J, Erfle V. Expression of protooncogenes in murine osteosarcomas. Int J Cancer 1986; 38: 67–74.
- 31 Silver J, Mohaideen A, Atkinson G, Einhorn TA, Majeska RJ. Expression of c-fos mRNA during fracture healing in the rat. Trans Orthop Res Soc 1997; 22: 606.
- 32
Sunters A,
McCluskey J,
Grigoriadis AE.
Control of cell cycle gene expression in bone development and during c-fos-induced osteosarcoma formation.
Dev Genet
1998;
22: 386–97.
10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 33 Teofoli P, Barduagni S, Ribuffo M, Campanella A, De Pita O, Puddu P. Expression of bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci 1999; 22: 31–7.
- 34 Wang H, Rodgers WH, Chmell MJ, Svitek C, Schwartz H. Osteosarcoma oncogene expression detected by in situ hybridization. J Orthop Res 1995; 13: 671–8.
- 35 Wang ZQ, Grigoriadis AE, Mohle-Steinlein U, Wagner EF. A novel target cell for c-fos induced oncogenesis: development of chondrogenic tumors in embryonic stem cell chimeras. EMBO J 1991; 10: 2437–50.
- 36 Wang ZQ, Grigoriadis AE, Wagner EF. Stable murine chondrogenic cell lines derived from c-fos induced cartilage tumors. J Bone Miner Res 1993; 8: 839–47.
- 37 Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE. c-Fos-induced osteosarcoma formation in transgenic mice: co-operativity with c-jun and the role of endogenous c-fos. Cancer Res 1995; 55: 6244–51.
- 38 Ward JM, Young D. Histogenesis and morphology of periosteal sarcomas induced by FBJ virus in NIH Swiss mice. Cancer Res 1976; 36: 3985–92.
- 39 Wu JX, Carpenter PM, Gresens C, Keh R, Morris JWS, Mercola D. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 1990; 5: 989–1000.
- 40 Yabut SM, Kenan S, Sissons HA, Lewis MM. Malignant transformation of fibrous dysplasia: a case report and review of the literature. Clin Orthop 1988; 228: 281–9.
- 41 Zhu JD, Pan HO, Suzuki F, Takigawa M. Proto-oncogene expression in a human chondrosarcoma cell line: HCS-2/8. Jpn J Cancer Res 1994; 85: 364–71.